Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbSci ( (ABSI) ) has provided an update.
On March 24, 2026, Absci reported fourth quarter and full-year 2025 results, highlighting clinical progress on ABS-201, its anti-PRLR antibody for androgenetic alopecia and endometriosis, including successful dosing of the first three cohorts in the Phase 1/2a HEADLINE trial with favorable emerging safety data and new human ex vivo findings showing hair growth stimulation and stem cell niche regeneration. The company also unveiled generative AI advances with its Origin-1 platform for de novo monoclonal antibody design, strengthened its leadership by appointing former Vertex executive Ransi Somaratne as chief medical officer, reiterated development plans for ABS-201, ABS-101, ABS-301, and ABS-501 and future partnerships, and reported 2025 revenue of $2.8 million, a wider net loss of $115.2 million driven by higher R&D spending, and year-end liquidity of $144.3 million, which it expects will fund operations into the first half of 2028.
The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.
Spark’s Take on ABSI Stock
According to Spark, TipRanks’ AI Analyst, ABSI is a Neutral.
Overall score is held back primarily by weak financial performance (unprofitability and ongoing cash burn). Technicals are also soft in the near term, and valuation metrics provide limited support due to losses and no dividend. The key offset is a more positive earnings-call outlook driven by ABS-201 pipeline momentum and partnering plans.
To see Spark’s full report on ABSI stock, click here.
More about AbSci
Absci Corporation is a clinical-stage biopharmaceutical company that uses generative artificial intelligence and a synthetic biology data engine to design and develop novel biologic therapeutics. The company focuses on creating AI-designed antibodies and other biologics targeting difficult indications such as androgenetic alopecia, endometriosis, immuno-oncology, and HER2-positive cancers, while also pursuing drug creation partnerships with larger pharmaceutical firms.
Average Trading Volume: 3,466,330
Technical Sentiment Signal: Sell
Current Market Cap: $440.6M
See more data about ABSI stock on TipRanks’ Stock Analysis page.